COVID-19 Update – EAU Bamlanivimab

June 7, 2021

On April 16, the FDA revoked the Emergency Use Authorization (EUA) for bamlanivimab, when administered alone, due to a sustained increase in COVID-19 viral variants in the U.S. that are resistant to this antibody therapy. Read more here.

Learn more about Zotec Partners here.